Quarterly report [Sections 13 or 15(d)]

WARRANTS TO PURCHASE COMMON STOCK

v3.25.3
WARRANTS TO PURCHASE COMMON STOCK
 9 Months Ended
Sep. 30, 2025
Warrants To Purchase Common Stock  
WARRANTS TO PURCHASE COMMON STOCK

NOTE 15 – WARRANTS TO PURCHASE COMMON STOCK

 

The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at September 30, 2025:

 

Exercise     Number     Expiration  
Price     Outstanding     Date  
$ 1,056.00       4,585     April 2029  
$ 1,056.00       2,782     April 2029  
$ 1,056.00       2,172     April 2029  
$ 1,056.00       10,884     April 2029  
$ 1,600.00       36     October 2028  
$ 2,720.00       5,758     December 2028  
$ 3,200.00       22     August 2028  
          26,239        

 

During the nine months ended September 30, 2025, 13,666; 5,758 (as the Company received FDA acceptance of our NDA filing), and 1 warrants with an exercise price of $1,056, $1,776 and $364,800, respectively, expired.

 

During the nine months ended September 30, 2024, 113,155 prefunded common warrants were exercised.